Impact Biomedical Inc (IBO) Announces 3F™ US Patent Issue
Rhea-AI Summary
Impact Biomedical (IBO) has secured U.S. patent No. 12,357,584 B2 for its 3F™ technology platform, focusing on controlling infectious diseases through plant-based functional fragrances. The patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.
The technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77%. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
Positive
- Secured new US patent valid until December 2038, expanding intellectual property portfolio
- Technology shows potential effectiveness against multiple major pathogens including MRSA and tuberculosis
- Targeting growing infectious disease market projected to reach $34B by 2023
- Active discussions ongoing with potential commercial partners
Negative
- Product still requires development and commercialization before generating revenue
- Potential competition from existing infectious disease treatments
News Market Reaction 2 Alerts
On the day this news was published, IBO gained 2.36%, reflecting a moderate positive market reaction. Argus tracked a trough of -12.1% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $166K to the company's valuation, bringing the market cap to $7M at that time.
Data tracked by StockTitan Argus on the day of publication.
HOUSTON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBO) is pleased to announce that the US Patent and Trademark Office has issued U.S. patent No. 12,357,584 B2 entitled “Composition and Method of Controlling Infectious Diseases with Functional Fragrances,” developed within IBO’s 3F™ technology platform.
This patent relates to unique composition and method for controlling infectious diseases. It includes compositions and formulations of constituents found in plants and fragrances produced by plants, with potential application as an antibacterial or antiviral agent. This patent will expire on December 7, 2038.
This expands Impact Biomedical’s 3F™ patent estate which includes insect repellent compositions and anti-microbial applications in the United States and other countries. It also further demonstrates IBO’s commitment to discovering, developing, and patenting unique technologies to meet unmet needs in human healthcare.
These compositions and formulations have unique antimicrobial and antiviral properties. The compositions can be formulated to treat or limit the occurrence of various diseases and to kill and/or be used as a disinfectant against various microbes, pathogens, and the like.
Potential applications include killing microbes as a disinfectant and to be administered to a patient to treat an infectious disease condition. The composition has potential effectiveness against various pathogens including but not limited to E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis.
Infectious diseases, caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, continue to pose significant global health challenges, driving demand for new offerings and solutions in both established and developing regions worldwide.
The worldwide infectious disease market is projected to grow from
Upon notification of the patent issue, IBO CEO Frank Heuszel said, “This is another demonstration of success with our business model delivering new unique proprietary technology with the potential to address unmet needs in human healthcare. We continue discussions with potential partners to move 3F™ towards the market in the US and other countries worldwide.”
About IBO:
Impact Biomedical Inc. (IBIO) discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com
FAQ
What is Impact Biomedical's (IBO) new patent for?
When does Impact Biomedical's new 3F™ patent expire?
What pathogens can Impact Biomedical's 3F™ technology potentially treat?
What is the market size for infectious diseases that Impact Biomedical is targeting?
How does Impact Biomedical plan to commercialize its 3F™ technology?
